Clinical trials
Advanced Esophageal Adenocarcinoma clinical trials
Below are recruiting advanced esophageal adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 74 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06469944RecruitingPhase 1/Phase 2
Study of drug combinations for stomach or esophagus cancer
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
Tucson, ArizonaAges 18 years+ - NCT07182149RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Denver, ColoradoAges 18 years+ - NCT06808971RecruitingPhase 2
Perioperative drug combo for advanced stomach cancer
This study tests a combination of four drugs given before and after surgery for a type of stomach or throat-stomach cancer that can be removed. The drugs are adebrelimab (immunotherapy), nab-paclitaxel, oxaliplatin, and tegafur. The goal is to see if this combination works better than standard treatments.
BeijingAges 18–75 - NCT07284186RecruitingPhase 1
Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Scottsdale, ArizonaAges 18 years+ - NCT06324357RecruitingPhase 1/Phase 2
Zongertinib for HER2-positive cancers that have spread
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
Cerritos, CaliforniaAges 18 years+ - NCT06532799RecruitingPhase 1/Phase 2
TIL therapy with pembrolizumab for advanced stomach and esophageal cancer
This trial tests a combination of immune cells from your tumor (TILs) and an immunotherapy drug (pembrolizumab) for stomach or esophageal cancer that has spread or returned after other treatments. It may help if standard options have failed.
Beijing, Beijing MunicipalityAges 16–90 - NCT06773507RecruitingPhase 1
Study of BC008-1A for advanced solid tumors
This trial tests a new drug called BC008-1A for people with advanced esophageal cancer or non-small cell lung cancer that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
TianjinAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT07152405RecruitingPhase 3
New drug vs. chemo for HER2+ stomach cancer
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy for people with HER2-positive stomach or gastroesophageal junction cancer that has spread. The goal is to see if BL-M07D1 works better than standard chemo.
Harbin, HeilongjiangAges 18–75 - NCT05403242RecruitingPhase 1/Phase 2
Study drug RC48-ADC plus S-1 for advanced HER2 stomach cancers
This Phase 1/2 study tests RC48-ADC (an antibody-drug treatment) together with S-1 (a chemotherapy medicine) in people with advanced stomach or esophagus/gastroesophageal junction cancer. It’s mainly for cancers with HER2 testing results of IHC 2+ and FISH-negative, and aims to find a safe dose and how well the treatment works as a first treatment option.
BeijingAges 18 years+ - NCT07481357RecruitingPhase 1
DA 3501 for advanced stomach or pancreatic cancer
This trial tests a new drug, DA 3501, in people with advanced stomach or pancreatic cancer that has a specific protein called CLDN18.2. It aims to see if the drug is safe and effective.
Seongnam, BundangAges 19 years+ - NCT06445972RecruitingPhase 1/Phase 2
Testing combination therapies for advanced stomach or esophageal cancer
This study tests new drug combinations for people with advanced stomach or esophageal cancer that worsened after first treatment. It aims to find better options for those whose tumors lack HER2.
Tucson, ArizonaAges 18 years+ - NCT04114136RecruitingPhase 2
Study tests pembrolizumab or nivolumab plus a diabetes-like drug
This Phase 2 study tests whether adding a metabolic (diabetes-related) medicine to an immune therapy (pembrolizumab or nivolumab) can better control certain solid tumors. It may help people whose standard treatment would usually be pembrolizumab or nivolumab alone.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+ - NCT03964753RecruitingPhase 2
Chemo before surgery for middle-lower esophageal cancer
This trial tests a chemotherapy combination (nab-paclitaxel plus cisplatin) given before surgery for locally advanced, operable esophageal squamous cell cancer. It aims to shrink the tumor and improve outcomes by treating cancer earlier while it’s still in one region.
Shijiazhuang, HebeiAges 18–75 - NCT06329869RecruitingPhase 2
A study of sacituzumab govitecan for advanced esophageal cancer
This trial tests a drug called sacituzumab govitecan for people with advanced esophageal squamous cell carcinoma that has already been treated with chemotherapy and immunotherapy. The drug targets a protein called Trop-2 on cancer cells to try to stop tumor growth.
TaipeiAges 18 years+ - NCT06496789RecruitingPhase 2
Immunotherapy plus chemo before surgery for stomach cancer
This trial tests a new immunotherapy drug (serplulimab) combined with standard chemotherapy before surgery for patients with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
TianjinAges 18–75 - NCT07069712RecruitingPhase 2
New drug combos before and after surgery for stomach or esophageal cancer
This trial is testing new drug combinations given before and after surgery for stomach or esophageal cancer that can be removed. The goal is to see if these treatments work better than standard care. You may be eligible if your tumor has certain markers and you haven't had treatment for this cancer yet.
Newark, DelawareAges 18 years+ - NCT07432295RecruitingPhase 2
Givastomig plus nivolumab and chemo for advanced stomach cancer
This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.
Goodyear, ArizonaAges 18 years+ - NCT06199895RecruitingPhase 2
Study of paclitaxel for patients with taxane-resistant solid tumors
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
Wuhan, HubeiAges 18 years+ - NCT05170503RecruitingPhase 2
Immunotherapy plus chemo before surgery for junction stomach cancers
This Phase 2 study tests giving immunotherapy together with chemotherapy before surgery for certain “locally advanced” cancers at the esophagus-stomach junction. It may help shrink the tumor and improve outcomes by treating the cancer earlier with both immune and chemotherapy approaches.
Guangzhou, GuangdongAges 18–75 - NCT07408505Recruiting
New appetite drug for weight loss in advanced pancreatic cancer
This trial tests a new form of a drug (nano-megestrol acetate) to help people with advanced pancreatic cancer who are losing weight and have poor appetite. It aims to see if it can improve cachexia, a condition of severe weight loss and muscle wasting.
JinanAges 18–75 - NCT07632079RecruitingPhase 2
Fast-Track Radiation and Chemotherapy for Esophageal Cancer
This study tests a shorter course of combined radiation therapy and chemotherapy (using drugs called paclitaxel and carboplatin) to treat esophageal cancer with the goal of curing it. The faster treatment schedule may help patients finish therapy sooner while still being effective.
AmsterdamAges 18 years+ - NCT06764355RecruitingPhase 2
Chemo, Immunotherapy, and Chemoradiation Before Surgery for Advanced Esophageal Cancer
This trial tests a combination of chemotherapy, immunotherapy, and chemoradiation before surgery for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
TaipeiAges 18–75
Hear when a new Advanced Esophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced esophageal adenocarcinoma?
- Yes. Clin2 currently lists 74 recruiting advanced esophageal adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced esophageal adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced esophageal adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Esophageal Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Locally Advanced Gastric Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Esophageal Squamous Cell Carcinoma
- Advanced Gastroesophageal Junction Adenocarcinoma
- Clinical Stage III Esophageal Adenocarcinoma AJCC v8
- Clinical Stage II Esophageal Adenocarcinoma AJCC v8
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.